Form 8-K - Current report:
SEC Accession No. 0001178670-24-000052
Filing Date
2024-10-31
Accepted
2024-10-31 08:10:28
Documents
15
Period of Report
2024-10-31
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alny-20241031.htm   iXBRL 8-K 27056
2 EX-99 alny2024q3earningsrelease.htm EX-99 294938
6 GRAPHIC logoforera.jpg GRAPHIC 4595
  Complete submission text file 0001178670-24-000052.txt   483797

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alny-20241031.xsd EX-101.SCH 1854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alny-20241031_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alny-20241031_pre.xml EX-101.PRE 13115
17 EXTRACTED XBRL INSTANCE DOCUMENT alny-20241031_htm.xml XML 2850
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 241412544
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)